HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The analyst cut estimates for 2023 due to the high base in 2022 with large COVID-19-related revenue and continued uncertainties such as Gland Pharma’s recovery.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>